EKF Diagnostics has agreed to acquire 360 Genomics, which specializes in mutation detection technology, for $2.4 million worth of company stock and as much as $12.1 million in milestone cash payments. The deal will allow EKF to expand its point-of-care testing portfolio as well as make inroads in the molecular diagnostics arena.
EKF moves to make inroads in molecular Dx market
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|